Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | PREP | P48147 | 1/20 | 0.53 |
| ▸ | FAP | Q12884 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794824 | 1.00 | LMNA (0.60) | LMNAGPR132HDAC1HDAC6HIF1A | |
| SCHEMBL2797592 | 1.00 | LMNA (0.60) | LMNAGPR132HDAC1HDAC6HIF1A | |
| SCHEMBL29748479 | 1.00 | LMNA (0.60) | LMNAGPR132HDAC1HDAC6HIF1A | |
| SCHEMBL30151637 | 1.00 | LMNA (0.60) | LMNAGPR132HDAC1HDAC6HIF1A | |
| Hydrochloric Acid SCHEMBL8439654 | 0.98 | GPR132 (0.59) | LMNAGPR132HDAC1HDAC6HIF1A | |
| SCHEMBL6860757 | 0.87 | HDAC1 (0.57) | LMNAHDAC1HDAC6HIF1ANPC1 | |
| SCHEMBL8804879 | 0.86 | LMNA (0.56) | LMNAHDAC1HDAC6HIF1ANPC1 | |
| SCHEMBL6574004 | 0.86 | LMNA (0.56) | LMNAHDAC1HDAC6HIF1ANPC1 | |
| SCHEMBL1106964 | 0.85 | HDAC1 (0.62) | LMNAHDAC1HDAC6HIF1ANPC1 | |
| SCHEMBL14660470 | 0.84 | KMT2A (0.59) | LMNAGPR132HIF1ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101289421-A | Method for synthesizing nicotinyl amino acids and sensitizing effect thereof to tumor radiotherapy | RADIOLOGY RES INST CHINESE ACA (CN) | 2008-10-22 | — | — | CN | claimed |
| US-5916906-A | TREATMENT OF NEURODEGENERATIVE DISORDERS, VIRAL INFECTIONS, AUTOIMMUNE DISEASES | SHASKAN EDWARD G (US) | 1999-06-29 | — | — | US | claimed |
| EP-0814812-A1 | COMPOSITIONS COMPRISING NICOTYNYLALANINE AND AN INHIBITOR OF GLYCINE CONJUGATION OR VITAMIN B6 | Shaskan, Edward G. (US) | 1998-01-07 | — | — | EP | claimed |
| WO-1996028167-A1 | COMPOSITIONS COMPRISING NICOTYNYLALANINE AND AN INHIBITOR OF GLYCINE CONJUGATION OR VITAMIN B6 | SHASKAN EDWARD G (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0532545-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.p.A. (IT) | 1993-03-24 | — | — | EP | claimed |
| WO-1991017750-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.P.A. (IT) | 1991-11-28 | — | — | WO | claimed |
| US-20240392273-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-3624846-B1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A COMBINATION OF NICOTINIC ACID AND TRYOPTOPHAN | BHAMIS RES LABORATORY PVT LTD (IN) | 2024-08-07 | — | — | EP | disclosed |
| EP-4401758-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Takeda Pharmaceutical Company Limited (JP) | 2024-07-24 | — | — | EP | disclosed |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-11 | — | — | US | disclosed |
| US-20240116864-A1 | XANTHOPHYLL DERIVATIVES | ALMARSSON ORN (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230355550-A1 | KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-09 | — | — | US | disclosed |
| US-11753378-B2 | Ketamine compounds and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-0532545-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.p.A. (IT) | 1993-03-24 | — | — | EP | disclosed |
| EP-0532545-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.p.A. (IT) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991017750-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.P.A. (IT) | 1991-11-28 | — | — | WO | disclosed |
| WO-1991017750-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.P.A. (IT) | 1991-11-28 | — | — | WO | disclosed |
| US-4394520-A | SKIN DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-07-19 | — | — | US | disclosed |
| US-4204064-A | FOR TREATMENT OF SKIN OR SCALP | L'OREAL (FR) | 1980-05-20 | — | — | US | disclosed |
| US-4085217-A | DERIVATIVES OF CYSTEINE OR CYSTEAMINE | L'OREAL (FR) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753378-B2 | Ketamine compounds and processes for making and using them | OPRK1, GRIK3, GRIN3B | LMNA 3498/4885GPR132 2192/4885HDAC1 3188/4885 |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | LMNA 2955/4885GPR132 4354/4885HDAC1 4227/4885 |
| US-20230355550-A1 | KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | OPRK1, GRIK3, GRIN3B | LMNA 3498/4885GPR132 2192/4885HDAC1 3188/4885 |
| US-20240116864-A1 | XANTHOPHYLL DERIVATIVES | XDH, FDFT1, FDPS | LMNA 619/4885GPR132 3005/4885HDAC1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.